- Home
- Applications
- USA
- bowel
Show results for
Refine by
Bowel Product Applications In Usa
6 applications found
An estimated 20 million people in the U.S. struggle with bowel incontinence, and an estimated 80% suffer in silence. Secca therapy is a safe, effective, minimally invasive procedure to treat bowel incontinence. ...
ByRestech based in Houston, TEXAS (USA)
A defective gastrointestinal (GI) barrier is associated with multiple conditions of high unmet need, including inflammatory bowel disease, chemotherapy-induced gut injury, food allergies, and celiac disease. ...
ByKallyope Inc. based in New York City, NEW YORK (USA)
ARM & HAMMER™ Sodium Bicarbonate is the trusted brand for formulation of healthcare products. Whether the application is as an active pharmaceutical ingredient or an excipient, manufacturers have come to rely on the consistent quality, regulatory compliance and technical support that come with the ARM & HAMMER™ brand. Explore the uses of sodium bicarbonate in pharmaceutical applications and dialysis by clicking on the links above or access product data using the menu to the ...
ByChurch & Dwight, Inc. based in Princeton, NEW JERSEY (USA)
Longitudinal imaging of pancreatic cancer. Monitor in a minimally invasive manner both tissue morphology and fibrosis (fluorescein) and cathepsin activity (Prosense® 680). A very thin probe (S 650) was used to monitor the pancreas of the same mouse over 9 months. ...
ByMauna Kea Technologies based in Paris, FRANCE
Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of ...
ByFinch Therapeutics Group, Inc. based in Somerville, MASSACHUSETTS (USA)
Standard treatment for advanced colorectal cancer generally involves surgical resection and chemotherapy. However, the recent emergence of targeted therapies, particularly those that inhibit EGFR, has provided treatment options that extend survival for a subset of patients. Unfortunately, this benefit does not extend to patients whose tumors contain mutations in EGFR signaling components KRAS and BRAF, which together represent 50% of all colorectal cancers. This makes characterizing these molecular markers an ...
ByBiocept based in San Diego, CALIFORNIA (USA)